1
|
Immune-correlates analysis of an HIV-1 vaccine efficacy trial.
|
N Engl J Med
|
2012
|
12.98
|
2
|
The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection.
|
J Exp Med
|
2009
|
6.22
|
3
|
Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys.
|
Nature
|
2012
|
5.49
|
4
|
Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2.
|
Immunity
|
2013
|
4.82
|
5
|
A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays.
|
J Immunol Methods
|
2002
|
4.48
|
6
|
Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family.
|
J Virol
|
2012
|
2.74
|
7
|
Results of an ELISPOT proficiency panel conducted in 11 laboratories participating in international human immunodeficiency virus type 1 vaccine trials.
|
AIDS Res Hum Retroviruses
|
2005
|
2.69
|
8
|
Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG.
|
Proc Natl Acad Sci U S A
|
2013
|
2.69
|
9
|
Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers.
|
AIDS
|
2009
|
2.53
|
10
|
Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination.
|
Sci Transl Med
|
2014
|
2.47
|
11
|
HIV evolution in early infection: selection pressures, patterns of insertion and deletion, and the impact of APOBEC.
|
PLoS Pathog
|
2009
|
2.15
|
12
|
High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responses.
|
Cytometry A
|
2011
|
2.14
|
13
|
Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infection.
|
Proc Natl Acad Sci U S A
|
2005
|
2.10
|
14
|
Vertical T cell immunodominance and epitope entropy determine HIV-1 escape.
|
J Clin Invest
|
2012
|
2.05
|
15
|
Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers.
|
Vaccine
|
2006
|
1.97
|
16
|
Interaction with cellular CD4 exposes HIV-1 envelope epitopes targeted by antibody-dependent cell-mediated cytotoxicity.
|
J Virol
|
2013
|
1.93
|
17
|
Lymph node T cell responses predict the efficacy of live attenuated SIV vaccines.
|
Nat Med
|
2012
|
1.86
|
18
|
Phenotypic and functional profile of HIV-inhibitory CD8 T cells elicited by natural infection and heterologous prime/boost vaccination.
|
J Virol
|
2010
|
1.81
|
19
|
Standardization and validation issues of the ELISPOT assay.
|
Methods Mol Biol
|
2005
|
1.79
|
20
|
Prevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccine.
|
J Infect Dis
|
2011
|
1.76
|
21
|
Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial.
|
J Acquir Immune Defic Syndr
|
2007
|
1.73
|
22
|
Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults.
|
Vaccine
|
2007
|
1.73
|
23
|
Prolonged CD4+ cell/virus load discordance during treatment with protease inhibitor-based highly active antiretroviral therapy: immune response and viral control.
|
J Infect Dis
|
2003
|
1.71
|
24
|
Induction of plasma (TRAIL), TNFR-2, Fas ligand, and plasma microparticles after human immunodeficiency virus type 1 (HIV-1) transmission: implications for HIV-1 vaccine design.
|
J Virol
|
2008
|
1.69
|
25
|
Perforin and IL-2 upregulation define qualitative differences among highly functional virus-specific human CD8 T cells.
|
PLoS Pathog
|
2010
|
1.59
|
26
|
Fitness costs and diversity of the cytotoxic T lymphocyte (CTL) response determine the rate of CTL escape during acute and chronic phases of HIV infection.
|
J Virol
|
2011
|
1.57
|
27
|
Measurement of cytokine release at the single cell level using the ELISPOT assay.
|
Methods
|
2006
|
1.57
|
28
|
CD4+CD8+ T cells represent a significant portion of the anti-HIV T cell response to acute HIV infection.
|
J Immunol
|
2012
|
1.57
|
29
|
Surface expression patterns of negative regulatory molecules identify determinants of virus-specific CD8+ T-cell exhaustion in HIV infection.
|
Blood
|
2011
|
1.52
|
30
|
High-dose recombinant Canarypox vaccine expressing HIV-1 protein, in seronegative human subjects.
|
J Infect Dis
|
2005
|
1.49
|
31
|
HIV-1 gp120 vaccine induces affinity maturation in both new and persistent antibody clonal lineages.
|
J Virol
|
2012
|
1.39
|
32
|
Antibodies with high avidity to the gp120 envelope protein in protection from simian immunodeficiency virus SIV(mac251) acquisition in an immunization regimen that mimics the RV-144 Thai trial.
|
J Virol
|
2012
|
1.37
|
33
|
Cross-sectional detection of acute HIV infection: timing of transmission, inflammation and antiretroviral therapy.
|
PLoS One
|
2011
|
1.32
|
34
|
Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees.
|
J Virol
|
2013
|
1.26
|
35
|
Neutralizing and other antiviral antibodies in HIV-1 infection and vaccination.
|
Curr Opin HIV AIDS
|
2007
|
1.24
|
36
|
SIVmac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responses.
|
Vaccine
|
2011
|
1.23
|
37
|
Discriminating between latent and active tuberculosis with multiple biomarker responses.
|
Tuberculosis (Edinb)
|
2011
|
1.22
|
38
|
Optimization of storage and shipment of cryopreserved peripheral blood mononuclear cells from HIV-infected and uninfected individuals for ELISPOT assays.
|
J Immunol Methods
|
2010
|
1.22
|
39
|
FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial.
|
J Clin Invest
|
2014
|
1.18
|
40
|
HIV-specific functional antibody responses in breast milk mirror those in plasma and are primarily mediated by IgG antibodies.
|
J Virol
|
2011
|
1.15
|
41
|
Acute HIV-1 infection in the Southeastern United States: a cohort study.
|
AIDS Res Hum Retroviruses
|
2012
|
1.14
|
42
|
Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells.
|
J Clin Invest
|
2015
|
1.13
|
43
|
Initial HIV-1 antigen-specific CD8+ T cells in acute HIV-1 infection inhibit transmitted/founder virus replication.
|
J Virol
|
2012
|
1.13
|
44
|
Protection afforded by an HIV vaccine candidate in macaques depends on the dose of SIVmac251 at challenge exposure.
|
J Virol
|
2013
|
1.12
|
45
|
A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects.
|
Vaccine
|
2011
|
1.11
|
46
|
Antigen-specific T-cell-mediated immunity after HIV-1 infection: implications for vaccine control of HIV development.
|
Expert Rev Vaccines
|
2006
|
1.10
|
47
|
Impact of immune escape mutations on HIV-1 fitness in the context of the cognate transmitted/founder genome.
|
Retrovirology
|
2012
|
1.10
|
48
|
Epitope specificity of human immunodeficiency virus-1 antibody dependent cellular cytotoxicity [ADCC] responses.
|
Curr HIV Res
|
2013
|
1.09
|
49
|
High antibody-dependent cellular cytotoxicity responses are correlated with strong CD8 T cell viral suppressive activity but not with B57 status in HIV-1 elite controllers.
|
PLoS One
|
2013
|
1.07
|
50
|
Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial.
|
Vaccine
|
2008
|
1.06
|
51
|
Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection.
|
AIDS
|
2011
|
0.99
|
52
|
Maternal HIV-1 envelope-specific antibody responses and reduced risk of perinatal transmission.
|
J Clin Invest
|
2015
|
0.98
|
53
|
Distinct kinetics of Gag-specific CD4+ and CD8+ T cell responses during acute HIV-1 infection.
|
J Immunol
|
2012
|
0.98
|
54
|
Toll-like receptor 7/8 (TLR7/8) and TLR9 agonists cooperate to enhance HIV-1 envelope antibody responses in rhesus macaques.
|
J Virol
|
2014
|
0.98
|
55
|
Mucosal immunization of lactating female rhesus monkeys with a transmitted/founder HIV-1 envelope induces strong Env-specific IgA antibody responses in breast milk.
|
J Virol
|
2013
|
0.95
|
56
|
Antiretroviral therapy initiated during acute HIV infection fails to prevent persistent T-cell activation.
|
J Acquir Immune Defic Syndr
|
2013
|
0.95
|
57
|
Longitudinal assessment of immune response and viral characteristics in HIV-infected patients with prolonged CD4(+)/viral load discordance.
|
AIDS Res Hum Retroviruses
|
2005
|
0.94
|
58
|
Isolation of HIV-1-neutralizing mucosal monoclonal antibodies from human colostrum.
|
PLoS One
|
2012
|
0.89
|
59
|
Immunodominance and cross-reactivity of B5703-restricted CD8 T lymphocytes from HIV type 1 subtype C-infected Ethiopians.
|
AIDS Res Hum Retroviruses
|
2005
|
0.87
|
60
|
Loss of DNAM-1 contributes to CD8+ T-cell exhaustion in chronic HIV-1 infection.
|
Eur J Immunol
|
2010
|
0.86
|
61
|
A cluster of HIV type 1 subtype C sequences from Ethiopia, observed in full genome analysis, is not sustained in subgenomic regions.
|
AIDS Res Hum Retroviruses
|
2003
|
0.85
|
62
|
Naïve T cells are maintained in the periphery during the first 3 months of acute HIV-1 infection: implications for analysis of thymus function.
|
J Clin Immunol
|
2005
|
0.84
|
63
|
Comparison of systemic and mucosal immunization with helper-dependent adenoviruses for vaccination against mucosal challenge with SHIV.
|
PLoS One
|
2013
|
0.83
|
64
|
Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge.
|
Vaccine
|
2012
|
0.80
|
65
|
Fixed-dose combination emtricitabine/tenofovir/efavirenz initiated during acute HIV infection; 96-week efficacy and durability.
|
AIDS
|
2016
|
0.78
|
66
|
Massive CD8 T cell response to primary HIV infection in the setting of severe clinical presentation.
|
AIDS Res Hum Retroviruses
|
2012
|
0.76
|
67
|
Gnidimacrin, a Potent Anti-HIV Diterpene, Can Eliminate Latent HIV-1 Ex Vivo by Activation of Protein Kinase C β.
|
J Med Chem
|
2015
|
0.75
|
68
|
[The sentinel lymph node biopsy. Evolution and convalidation of the technique].
|
Ann Ital Chir
|
2008
|
0.75
|
69
|
Corrigendum: Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition.
|
Nat Med
|
2016
|
0.75
|